Present and Future in Treatment of Hodgkin Lymphoma.
Journal
Maedica
ISSN: 1841-9038
Titre abrégé: Maedica (Bucur)
Pays: Romania
ID NLM: 101526930
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
17
9
2019
pubmed:
17
9
2019
medline:
17
9
2019
Statut:
ppublish
Résumé
Hodgkin lymphoma is a highly curable malignant hemopathy, using chemotherapy, radiotherapy, target therapies and hematopoietic stem cell transplantation. Current research in this field focuses on identifying prognostic factors associated with the pathogenic characteristics of the tumoral process, enabling the therapy to be adjusted to each patient's degree of risk. The identification of biomarkers associated with the tumoral process is extremely important because these molecules can be targets for new biological therapies.
Identifiants
pubmed: 31523296
doi: 10.26574/maedica.2019.14.2.144
pmc: PMC6709391
doi:
Types de publication
Editorial
Langues
eng
Pagination
144-147Références
Br J Haematol. 2003 Sep;122(5):718-27
pubmed: 12930382
Lancet Oncol. 2004 Jan;5(1):11-8
pubmed: 14700604
J Clin Oncol. 2005 Sep 10;23(26):6379-86
pubmed: 16155023
J Clin Oncol. 2005 Sep 10;23(26):6400-8
pubmed: 16155026
N Engl J Med. 2010 Nov 4;363(19):1812-21
pubmed: 21047225
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Lancet Oncol. 2015 Mar;16(3):284-92
pubmed: 25683846
Lancet. 2015 May 9;385(9980):1853-62
pubmed: 25796459
Clin Cancer Res. 2017 Mar 1;23(5):1156-1166
pubmed: 27582488
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Blood. 2018 Mar 15;131(11):1183-1194
pubmed: 29229594
Blood. 2018 Jul 5;132(1):40-48
pubmed: 29703778